Benchmark Downgrades CryoLife (CRY) to Hold

Benchmark downgraded CryoLife (NYSE: CRY) from Buy to Hold with a price target of $6.00 (from $7.50).

Analyst Raymond Myers said "We are lowering our rating to Hold following Q2 results as PerClot’s FDA clinical trial enrollment was delayed from mid-2012 to early 2013. We believe this shift is benefiting 2012 results through lower R&D expenditure, at the expense of 2013. We now forecast meaningful earnings expansion beginning in 2014. Our lowered $6.00 price target is 20x $0.37 EPS in 2014, discounted one year at 25%, plus $0.34 per share in cash."

For an analyst ratings summary and ratings history on CryoLife click here. For more ratings news on CryoLife click here.

Shares of CryoLife closed at $5.21 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Stifel Starts Tower Semiconductor (TSEM) at Buy, Top Pick
• Everus Construction Group acquires Epsilon Industries for $295M
• California Resources completes $63M acquisition of Crimson Midstream